Reuters -- Schering-Plough Corp's injectable drug PegIntron carries "substantial toxicity" and had no effect on overall survival in melanoma skin cancer patients undergoing surgery, U.S. Food and Drug Administration staff reviewers said in documents released on Thursday.
